Skip to main content

Drug Interactions between AccessPak for HIV PEP Expanded with Viracept and Axid AR

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

nizatidine nelfinavir

Applies to: Axid AR (nizatidine) and AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir)

There is currently no information in the medical literature regarding a potential interaction between nelfinavir and H2-receptor antagonists. Nelfinavir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) decreased by 37%, 36% and 39%, respectively, when nelfinavir (1250 mg twice daily) was coadministered with omeprazole (40 mg once daily 30 minutes before nelfinavir) for 4 days, presumably due to decreased solubility of nelfinavir as gastric pH increased. Although theoretically possible, it is not certain to what extent such an interaction may occur with H2-receptor antagonists, or whether it is clinically relevant. Caution may be advisable during coadministration.

References

  1. "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc PROD (2001):

Switch to consumer interaction data

Drug and food interactions

Minor

tenofovir food

Applies to: AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir)

Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.

References

  1. "Product Information. Viread (tenofovir)." Gilead Sciences (2001):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer